Caribou Bio reported Q4 GAAP net loss of USD 26.5 million, or USD 0.28 per share, on licensing and collaboration revenue of USD 3.9 million. R&D expenses were USD 23.8 million and G&A expenses were USD 8.6 million in Q4. For FY 2025, Caribou Bio posted licensing and collaboration revenue of USD 11.2 million, R&D expenses of USD 109.4 million, and G&A expenses of USD 37.9 million. GAAP net loss was USD 148.1 million, or USD 1.59 per share, while non-GAAP net loss was USD 126.8 million, or USD 1.36 per share, excluding USD 21.3 million of non-recurring, non-cash impairment charges. Cash, cash equivalents, and marketable securities were USD 142.8 million at Dec. 31, 2025, and the company said it expects this to fund its current operating plan into 2H 2027 while it explores options to fully fund its planned vispa-cel pivotal trial. On the business side, Caribou Bio highlighted ANTLER phase 1 data for vispacabtagene regedleucel (vispa-cel, formerly CB-010) in second-line large B cell lymphoma and said it remains in ongoing engagement with the FDA on pivotal trial design, with longer follow-up from ANTLER expected in 2026. The company also said it initiated dose expansion for the CB-011 CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma, is enrolling both BCMA-naïve and prior BCMA-exposed patients, and expects to report initial dose expansion data and longer follow-up on dose escalation data in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603051605PRIMZONEFULLFEED9666920) on March 05, 2026, and is solely responsible for the information contained therein.
Comments